Forgot Password?
Return to Course Listing

CME: Multiple Myeloma (MM): Updates from 23rd Annual Congress of EHA (EHA 2018)


Activity Description / Statement of Need:

In this online, enduring self-learning activity:

Annual meetings of large, national, professional societies offer an opportunity for healthcare professionals to get a first glimpse at study results that have the potential to impact practice as provide a forum for an exchange of ideas and practices between thought leaders and less distinguished practitioners.  EHA 2018 is no exception.  Nevertheless, as with every meeting, many professionals from both the community and health-system settings alike will be unable to attend the conference for a variety of reasons, justifying the creation of educational programming that summarize the major findings presented at the meeting. 

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. While MM only makes up about 1% of all cancers, it the most common of the blood cancers with an incidence of a little under 31,000 and an annual mortality rate of just under 13,000. The peak incidence age of MM is at about 70 years of age, and the disease occurs twice as commonly in African Americans as it does in whites.

Target Audience:

The following healthcare professionals: hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

This activity is supported by educational grants from Amgen.

Learners may participate in this activity free of charge.

Release Date: April 25, 2019 -- Expiration Date: April 25, 2021

Faculty: Shaji Kumar, MD


Faculty member introduction, disclosures

MM treatment paradigm today

Patient scenario (revisited throughout activity)

MM major research findings from EHA 2018 related to:

  • Initial pharmacotherapy in transplant-eligible disease
  • Study of ASCT outcomes
  • Initial pharmacotherapy in transplant-ineligible disease
  • Management of relapse disease
  • Monoclonal antibodies
  • Novel immune therapies

Summary, conclusion, and best practice recap


Learning Objectives

By the end of the session the participant will be able to:

  • Recall initial treatment(s) of transplant-eligible and -ineligible disease and compose a care plan based on that information
  • Describe the role of autologous stem cell transplant (ASCT) and compose a care plan based on that information
  • Summarize the role and safety and efficacy profiles of monoclonal antibodies and compose a care plan based on that information
  • Recall the role and safety and efficacy profiles of novel immune therapies and compose a care plan based on that information



Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure:  Shaji Kumar, MD, Professor of Medicine - Mayo Clinic College of Medicine and Science; Master's Faculty Privileges in Clinical & Translational Sci. - Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science; Medical Director, Cancer Clinical Research Office - Mayo Clinic Cancer Center, discloses that he has received research grant support from: Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amge; and is a consultant for: Celgene, Takeda, Janssen, KITE, Merck, Abbvie, Medimmune, Genentech, Oncopeptides, Amgen, Reddys Labs.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, has no relevant financial disclosures.

Commercial Support Disclosure: This activity is supported by educational grants from Amgen.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Treating Oncology Patients During COVID-19

von Willebrand's disease (vWD): therapeutic updates and optimizing treatment

Contemporary approaches to advanced diffuse large B-cell lymphoma (DLBCL)

Transthyretin amyloidosis (ATTR) and its complications: Optimizing management strategies